BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26095521)

  • 1. Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.
    Shapiro EG; Nestrasil I; Rudser K; Delaney K; Kovac V; Ahmed A; Yund B; Orchard PJ; Eisengart J; Niklason GR; Raiman J; Mamak E; Cowan MJ; Bailey-Olson M; Harmatz P; Shankar SP; Cagle S; Ali N; Steiner RD; Wozniak J; Lim KO; Whitley CB
    Mol Genet Metab; 2015; 116(1-2):61-8. PubMed ID: 26095521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.
    Yund B; Rudser K; Ahmed A; Kovac V; Nestrasil I; Raiman J; Mamak E; Harmatz P; Steiner R; Lau H; Vekaria P; Wozniak JR; Lim KO; Delaney K; Whitley C; Shapiro EG
    Mol Genet Metab; 2015 Feb; 114(2):170-7. PubMed ID: 25541100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT).
    Shapiro E; Guler OE; Rudser K; Delaney K; Bjoraker K; Whitley C; Tolar J; Orchard P; Provenzale J; Thomas KM
    Mol Genet Metab; 2012 Sep; 107(1-2):116-21. PubMed ID: 22867884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of neurocognition in MPS disorders: A review.
    Shapiro EG; Eisengart JB
    Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
    Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB
    Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.
    Aldenhoven M; Wynn RF; Orchard PJ; O'Meara A; Veys P; Fischer A; Valayannopoulos V; Neven B; Rovelli A; Prasad VK; Tolar J; Allewelt H; Jones SA; Parini R; Renard M; Bordon V; Wulffraat NM; de Koning TJ; Shapiro EG; Kurtzberg J; Boelens JJ
    Blood; 2015 Mar; 125(13):2164-72. PubMed ID: 25624320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings.
    Yamazaki N; Kosuga M; Kida K; Takei G; Fukuhara Y; Matsumoto H; Senda M; Honda A; Ishiguro A; Koike T; Yabe H; Okuyama T
    Brain Dev; 2019 Jun; 41(6):546-550. PubMed ID: 30755342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation.
    Polgreen LE; Lund TC; Braunlin E; Tolar J; Miller BS; Fung E; Whitley CB; Eisengart JB; Northrop E; Rudser K; Miller WP; Orchard PJ
    Pediatr Res; 2020 Jan; 87(1):104-111. PubMed ID: 31434105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic cell transplantation for severe MPS I in the first six months of life: The heart of the matter.
    Braunlin E; Miettunen K; Lund T; Luquette M; Orchard P
    Mol Genet Metab; 2019 Feb; 126(2):117-120. PubMed ID: 30503158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I.
    Kovac V; Shapiro EG; Rudser KD; Mueller BA; Eisengart JB; Delaney KA; Ahmed A; King KE; Yund BD; Cowan MJ; Raiman J; Mamak EG; Harmatz PR; Shankar SP; Ali N; Cagle SR; Wozniak JR; Lim KO; Orchard PJ; Whitley CB; Nestrasil I
    Mol Genet Metab; 2022 Feb; 135(2):122-132. PubMed ID: 35012890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
    Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1.
    Grosse SD; Lam WKK; Wiggins LD; Kemper AR
    Genet Med; 2017 Sep; 19(9):975-982. PubMed ID: 28125077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I.
    King KE; Rudser KD; Nestrasil I; Kovac V; Delaney KA; Wozniak JR; Mueller BA; Lim KO; Eisengart JB; Mamak EG; Raiman J; Ali N; Cagle S; Harmatz P; Whitley CB; Shapiro EG
    Neurology; 2019 May; 92(20):e2321-e2328. PubMed ID: 30979856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
    Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
    Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.
    de Ru MH; Boelens JJ; Das AM; Jones SA; van der Lee JH; Mahlaoui N; Mengel E; Offringa M; O'Meara A; Parini R; Rovelli A; Sykora KW; Valayannopoulos V; Vellodi A; Wynn RF; Wijburg FA
    Orphanet J Rare Dis; 2011 Aug; 6():55. PubMed ID: 21831279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world.
    Muñoz-Rojas MV; Bay L; Sanchez L; van Kuijck M; Ospina S; Cabello JF; Martins AM
    J Inherit Metab Dis; 2011 Oct; 34(5):1029-37. PubMed ID: 21541721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of craniovertebral abnormalities in a single-center study in 54 patients with Hurler syndrome.
    Huang S; Nascene DR; Shanley R; Pena-Pino I; Lund TC; Gupta AO; Orchard PJ; Sandoval-Garcia C
    J Neurosurg Pediatr; 2024 Jun; 33(6):574-582. PubMed ID: 38489810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome.
    Eisengart JB; Jarnes J; Ahmed A; Nestrasil I; Ziegler R; Delaney K; Shapiro E; Whitley C
    Mol Genet Metab Rep; 2017 Dec; 13():64-68. PubMed ID: 28983455
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.